The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline.
Anxiety disorders
agoraphobia
consensus guideline
evidence-based care
generalized anxiety disorder
operational criteria
panic disorder
social anxiety disorder
treatment resistance
Journal
World psychiatry : official journal of the World Psychiatric Association (WPA)
ISSN: 1723-8617
Titre abrégé: World Psychiatry
Pays: Italy
ID NLM: 101189643
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
ppublish
Résumé
Anxiety disorders are very prevalent and often persistent mental disorders, with a considerable rate of treatment resistance which requires regulatory clinical trials of innovative therapeutic interventions. However, an explicit definition of treatment-resistant anxiety disorders (TR-AD) informing such trials is currently lacking. We used a Delphi method-based consensus approach to provide internationally agreed, consistent and clinically useful operational criteria for TR-AD in adults. Following a summary of the current state of knowledge based on international guidelines and an available systematic review, a survey of free-text responses to a 29-item questionnaire on relevant aspects of TR-AD, and an online consensus meeting, a panel of 36 multidisciplinary international experts and stakeholders voted anonymously on written statements in three survey rounds. Consensus was defined as ≥75% of the panel agreeing with a statement. The panel agreed on a set of 14 recommendations for the definition of TR-AD, providing detailed operational criteria for resistance to pharmacological and/or psychotherapeutic treatment, as well as a potential staging model. The panel also evaluated further aspects regarding epidemiological subgroups, comorbidities and biographical factors, the terminology of TR-AD vs. "difficult-to-treat" anxiety disorders, preferences and attitudes of persons with these disorders, and future research directions. This Delphi method-based consensus on operational criteria for TR-AD is expected to serve as a systematic, consistent and practical clinical guideline to aid in designing future mechanistic studies and facilitate clinical trials for regulatory purposes. This effort could ultimately lead to the development of more effective evidence-based stepped-care treatment algorithms for patients with anxiety disorders.
Types de publication
Journal Article
Langues
eng
Pagination
113-123Informations de copyright
© 2024 World Psychiatric Association.
Références
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Washington: American Psychiatric Association, 2013.
Wittchen HU, Jacobi F, Rehm J et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79.
Kessler RC, Petukhova M, Sampson NA et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21:169-84.
Kessler RC, Angermeyer M, Anthony JC et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007;6:168-76.
Craske MG, Stein MB, Eley TC et al. Anxiety disorders. Nat Rev Dis Primers 2017;3:17024.
Olesen J, Gustavsson A, Svensson M et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012;19:155-62.
Penninx BW, Pine DS, Holmes EA et al. Anxiety disorders. Lancet 2021;397:914-27.
Solis EC, van Hemert AM, Carlier IVE et al. The 9-year clinical course of depressive and anxiety disorders: new NESDA findings. J Affect Disord 2021;295:1269-79.
Baxter AJ, Vos T, Scott KM et al. The global burden of anxiety disorders in 2010. Psychol Med 2014;44:2363-74.
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022;9:137-50.
Chen MH, Tsai SJ. Treatment-resistant panic disorder: clinical significance, concept and management. Prog Neuropsychopharmacol Biol Psychiatry 2016;70:219-26.
Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci 2015;17:191-206.
Van Ameringen M, Mancini C, Pipe B et al. Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr 2004;9:753-62.
Freire RC, Zugliani MM, Garcia RF et al. Treatment-resistant panic disorder: a systematic review. Expert Opin Pharmacother 2016;17:159-68.
Bandelow B, Allgulander C, Baldwin DS et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. World J Biol Psychiatry 2023;24:79-117.
Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006;11:805-14.
Loerinc AG, Meuret AE, Twohig MP et al. Response rates for CBT for anxiety disorders: need for standardized criteria. Clin Psychol Rev 2015;42:72-82.
Sanderson WC, Bruce TJ. Causes and management of treatment-resistant panic disorder and agoraphobia: a survey of expert therapists. Cogn Behav Pract 2007;14:26-35.
Taylor S, Abramowitz JS, McKay D. Non-adherence and non-response in the treatment of anxiety disorders. J Anxiety Disord 2012;26:583-9.
Yonkers KA, Bruce SE, Dyck IR et al. Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety 2003;17:173-9.
Springer KS, Levy HC, Tolin DF. Remission in CBT for adult anxiety disorders: a meta-analysis. Clin Psychol Rev 2018;61:1-8.
Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019;204:107402.
Bandelow B, Baldwin D, Abelli M et al. Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics. World J Biol Psychiatry 2016;17:321-65.
Bandelow B, Baldwin D, Abelli M et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 2017;18:162-214.
Vismara M, Girone N, Cirnigliaro G et al. Peripheral biomarkers in DSM-5 anxiety disorders: an updated overview. Brain Sci 2020;10:564.
Perna G, Caldirola D. Management of treatment-resistant panic disorder. Curr Treat Options Psychiatry 2017;4:371-86.
Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002;3:171-99.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 2003;37:641-56.
European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of panic disorder. Amsterdam: European Medicines Agency, 2005.
Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96.
Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51:9-91s.
Connolly SD, Bernstein GA. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007;46:267-83.
Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
Ministry of Health and Consumer Affairs. Clinical practice guideline for treatment of patients with anxiety disorders in primary care. Madrid: Ministry of Health and Consumer Affairs, 2008.
American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder, 2nd ed. Washington: American Psychiatric Association, 2009.
Levitan MN, Chagas MH, Crippa JA et al. Guidelines of the Brazilian Medical Association for the treatment of social anxiety disorder. Rev Brasil Psiquiatr 2011;33:292-302.
National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. London: National Institute for Health and Care Excellence, 2011.
Levitan MN, Chagas MH, Linares IM et al. Brazilian Medical Association guidelines for the diagnosis and differential diagnosis of panic disorder. Rev Brasil Psiquiatr 2013;35:406-15.
National Collaborating Centre for Mental Health. Social anxiety disorder: recognition, assessment and treatment. Leicester: British Psychological Society, 2013.
Seedat S. Social anxiety disorder (social phobia). S Afr J Psychiatr 2013;19:192-6.
Stein DJ. Generalised anxiety disorder. S Afr J Psychiatr 2013;19:175-9.
Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:403-39.
Bandelow B, Wiltink J, Alpers GW et al. S3-Leitlinie Behandlung von Angststörungen. Zurich: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, 2014.
Lim L, Chan HN, Chew PH et al. Ministry of Health clinical practice guidelines: anxiety disorders. Singapore Med J 2015;56:310-5.
Gautam S, Jain A, Gautam M et al. Clinical practice guidelines for the management of generalised anxiety disorder (GAD) and panic disorder (PD). Indian J Psychiatry 2017;59:S67-73.
Andrews G, Bell C, Boyce P et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry 2018;52:1109-72.
Yoon H, Oh DJ, Suh HS et al. Korean guidelines for the pharmacological treatment of social anxiety disorder: initial treatment strategies. Psychiatry Investig 2018;15:147-55.
Walter HJ, Bukstein OG, Abright AR et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2020;59:1107-24.
Bandelow B, Aden I, Alpers GW et al. S3-Leitlinie Behandlung von Angststörungen - Version 2. Zurich: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, 2021.
Bandelow B, Allgulander C, Baldwin DS et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD. World J Biol Psychiatry 2023;24:118-34.
Katzman MA, Bleau P, Blier P et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14(Suppl. 1):S1.
Australian Therapeutic Guidelines. https://tgldcdp.tg.org.au.
COMET Initiative. Core outcome measures in effectiveness trials. www.comet-initiative.org.
Obbarius A, van Maasakkers L, Baer L et al. Standardization of health outcomes assessment for depression and anxiety: recommendations from the ICHOM Depression and Anxiety Working Group. Qual Life Res 2017;26:3211-25.
Bokma WA, Wetzer G, Gehrels JB et al. Aligning the many definitions of treatment resistance in anxiety disorders: a systematic review. Depress Anxiety 2019;36:801-12.
Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry 2022;27:58-72.
Cantrill JA, Sibbald B, Buetow S. The Delphi and nominal group techniques in health services research. Int J Pharm Pract 1996;4:67-74.
Dalkey NC. The Delphi method: an experimental study of group opinion. Santa Monica: RAND Corporation, 1969.
Moher D, Schulz KF, Simera I et al. Guidance for developers of health research reporting guidelines. PLoS Med 2010;7:e1000217.
Trevelyan EG, Robinson PN. Delphi methodology in health research: how to do it? Eur J Integr Med 2015;7:423-8.
Jünger S, Payne SA, Brine J et al. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med 2017;31:684-706.
Sforzini L, Worrell C, Kose M et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry 2022;27:1286-99.
Fackrell K, Smith H, Colley V et al. Core Outcome Domains for early phase clinical trials of sound-, psychology-, and pharmacology-based interventions to manage chronic subjective tinnitus in adults: the COMIT'ID study protocol for using a Delphi process and face-to-face meetings to establish consensus. Trials 2017;18:388.
Vogel C, Zwolinsky S, Griffiths C et al. A Delphi study to build consensus on the definition and use of big data in obesity research. Int J Obes 2019;43:2573-86.
Knaapen M, Hall NJ, van der Lee JH et al. Establishing a core outcome set for treatment of uncomplicated appendicitis in children: study protocol for an international Delphi survey. BMJ Open 2019;9:e028861.
Santaguida P, Dolovich L, Oliver D et al. Protocol for a Delphi consensus exercise to identify a core set of criteria for selecting health related outcome measures (HROM) to be used in primary health care. BMC Fam Pract 2018;19:152.
Blade J, Calleja M, Lahuerta JJ et al. Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project. BMJ Open 2018;8:e018850.
Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
Cuijpers P, Li J, Hofmann SG et al. Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. Clin Psychol Rev 2010;30:768-78.
Ahmadzad-Asl M, Davoudi F, Mohamadi S et al. Systematic review and meta-analysis of the placebo effect in panic disorder: implications for research and clinical practice. Aust N Z J Psychiatry 2022;56:1130-41.
LeDoux JE, Hofmann SG. The subjective experience of emotion: a fearful view. Curr Opin Behav Sci 2018;19:67-72.
Taschereau-Dumouchel V, Michel M, Lau H et al. Putting the “mental” back in “mental disorders”: a perspective from research on fear and anxiety. Mol Psychiatry 2022;27:1322-30.
Mennin DS, Fresco DM, Heimberg RG et al. Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J Anxiety Disord 2002;16:661-73.
Pranckeviciene A, Saudargiene A, Gecaite-Stonciene J et al. Validation of the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder-7 in Lithuanian student sample. PLoS One 2022;17:e0263027.
Rutter LA, Brown TA. Psychometric properties of the Generalized Anxiety Disorder scale-7 (GAD-7) in outpatients with anxiety and mood disorders. J Psychopathol Behav Assess 2017;39:140-6.
Stanyte A, Fineberg NA, Podlipskyte A et al. Validation of the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder-7 in Lithuanian individuals with anxiety and mood disorders. J Psychiatr Res 2023;164:221-8.
Delgadillo J, Payne S, Gilbody S et al. Brief case finding tools for anxiety disorders: validation of GAD-7 and GAD-2 in addictions treatment. Drug Alcohol Depend 2012;125:37-42.
Pallanti S, Hollander E, Bienstock C et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-91.
Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-59.
Fekadu A, Wooderson S, Donaldson C et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009;70:177-84.
McIntyre RS, Alsuwaidan M, Baune BT et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023;22:394-412.
Bokma WA, Zhutovsky P, Giltay EJ et al. Predicting the naturalistic course in anxiety disorders using clinical and biological markers: a machine learning approach. Psychol Med 2022;52:57-67.
Alboni S, van Dijk RM, Poggini S et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry 2017;22:552-61.
Bokma WA, Batelaan NM, Hoogendoorn AW et al. A clinical staging approach to improving diagnostics in anxiety disorders: is it the way to go? Aust N Z J Psychiatry 2020;54:173-84.
Bokma WA, Batelaan NM, Penninx BWJH et al. Evaluating a dimensional approach to treatment resistance in anxiety disorders: a two-year follow-up study. J Affect Disord Rep 2021;4:100139.
Altamura AC, Dell'Osso B, D'Urso N et al. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr 2008;13:415-22.
McAllister-Williams RH, Arango C, Blier P et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord 2020;267:264-82.
Demyttenaere K. What is treatment resistance in psychiatry? A “difficult to treat” concept. World Psychiatry 2019;18:354-5.
Rush AJ, Sackeim HA, Conway CR et al. Clinical research challenges posed by difficult-to-treat depression. Psychol Med 2022;52:419-32.
Cieza A, Sabariego C, Anczewska M et al. PARADISE 24: a measure to assess the impact of brain disorders on people's lives. PLoS One 2015;10:e0132410.
Devji T, Carrasco-Labra A, Qasim A et al. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ 2020;369:m1714.
Bosman RC, van Balkom A, Rhebergen D et al. Predicting the course of anxiety disorders: the role of biological parameters. Prog Neuropsychopharmacol Biol Psychiatry 2020;101:109924.
Roseberry K, Le-Niculescu H, Levey DF et al. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry 2023; doi: 10.1038/s41380-023-01998-0.
Abi-Dargham A, Moeller SJ, Ali F et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 2023;22:236-62.
Stein DJ, Craske MG, Rothbaum BO et al. The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. World Psychiatry 2021;20:336-56.
Merikangas KR, Swendsen J, Hickie IB et al. Real-time mobile monitoring of the dynamic associations among motor activity, energy, mood, and sleep in adults with bipolar disorder. JAMA Psychiatry 2019;76:190-8.
Zhao N, Zhang Z, Wang Y et al. See your mental state from your walk: recognizing anxiety and depression through Kinect-recorded gait data. PLoS One 2019;14:e0216591.
Moore RC, Depp CA, Wetherell JL et al. Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults. J Psychiatr Res 2016;75:116-23.
McGinnis EW, Lunna S, Berman I et al. Discovering digital biomarkers of panic attack risk in consumer wearables data. medRxiv 2023:2023.03.01.23286647.
Gargon E, Crew R, Burnside G et al. Higher number of items associated with significantly lower response rates in COS Delphi surveys. J Clin Epidemiol 2019;108:110-20.
Maj M. Understanding depression beyond the “mind-body” dichotomy. World Psychiatry 2023;22:34-50.
Weissman MM. Does treatment-resistant depression need psychotherapy? World Psychiatry 2023;22:417-8.
Cuijpers P. From treatment resistance to sequential treatments of depression. World Psychiatry 2023;22:418-9.
Lenze EJ, Wetherell JL. A lifespan view of anxiety disorders. Dialogues Clin Neurosci 2011;13:381-99.
Wittchen HU, Lieb R, Pfister H et al. The waxing and waning of mental disorders: evaluating the stability of syndromes of mental disorders in the population. Compr Psychiatry 2000;41:122-32.
Kirkham JJ, Davis K, Altman DG et al. Core Outcome Set-STAndards for Development: the COS-STAD recommendations. PLoS Med 2017;14:e1002447.
Kirkham JJ, Gorst S, Altman DG et al. Core Outcome Set-STAndards for Reporting: the COS-STAR Statement. PLoS Med 2016;13:e1002148.
Barton S, Karner C, Salih F et al. Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technol Assess 2014;18:1-59.
Chiu A, Falk A, Walkup JT. Anxiety disorders among children and adolescents. Focus 2016;14:26-33.
Lydiard RB, Brawman-Mintzer O. Panic disorder across the life span: a differential diagnostic approach to treatment resistance. Bull Menninger Clin 1997;61:A66-94.
Reinblatt SP, Walkup JT. Psychopharmacologic treatment of pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am 2005;14:877-908.
Baldwin DS, Gordon R, Abelli M et al. The separation of adult separation anxiety disorder. CNS Spectr 2016;21:289-94.
Muris P, Ollendick TH. Children who are anxious in silence: a review on selective mutism, the new anxiety disorder in DSM-5. Clin Child Fam Psychol Rev 2015;18:151-69.
Schiele MA, Bandelow B, Baldwin DS et al. A neurobiological framework of separation anxiety and related phenotypes. Eur Neuropsychopharmacol 2020;33:45-57.
Lueken U, Zierhut KC, Hahn T et al. Neurobiological markers predicting treatment response in anxiety disorders: a systematic review and implications for clinical application. Neurosci Biobehav Rev 2016;66:143-62.
Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci 2017;19:93-107.
Reinhold JA, Mandos LA, Rickels K et al. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 2011;12:2457-67.
Ipser JC, Carey P, Dhansay Y et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev 2006;4:CD005473.
Diemer J, Vennewald N, Domschke K et al. Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety. Eur Arch Psychiatry Clin Neurosci 2010;260(Suppl. 2):S127-31.
Caletti E, Massimo C, Magliocca S et al. The role of the acceptance and commitment therapy in the treatment of social anxiety: an updated scoping review. J Affect Disord 2022;310:174-82.
Gloster AT, Rinner MTB, Ioannou M et al. Treating treatment non-responders: a meta-analysis of randomized controlled psychotherapy trials. Clin Psychol Rev 2020;75:101810.
Hoge EA, Bui E, Mete M et al. Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a randomized clinical trial. JAMA Psychiatry 2023;80:13-21.
Solem S, Wells A, Kennair LEO et al. Metacognitive therapy versus cognitive-behavioral therapy in adults with generalized anxiety disorder: a 9-year follow-up study. Brain Behav 2021;11:e2358.
Millard LA, Wan MW, Smith DM et al. The effectiveness of compassion focused therapy with clinical populations: a systematic review and meta-analysis. J Affect Disord 2023;326:168-92.
Singewald N, Sartori SB, Reif A et al. Alleviating anxiety and taming trauma: novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. Neuropharmacology 2023;226:109418.
Correll CU, Solmi M, Cortese S et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry 2023;22:48-74.